These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17425753)

  • 21. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
    Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
    Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
    Hirschberg Y; Karara AH; Pietri AO; McLeod JF
    Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
    Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
    Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
    Mori Y; Kuriyama G; Tajima N
    Endocrine; 2004 Dec; 25(3):203-6. PubMed ID: 15758246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
    Dimitriadis G; Boutati E; Lambadiari V; Mitrou P; Maratou E; Brunel P; Raptis SA
    Eur J Clin Invest; 2004 Jul; 34(7):490-7. PubMed ID: 15255786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
    González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
    J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
    Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
    Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
    Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.